Gilead Phase III trial of remdesivir for COVID-19 shows 65 percent are 'more likely' to improve by day 11

Gilead Phase III trial of remdesivir for COVID-19 shows 65 percent are 'more likely' to improve by day 11



Gilead Sciences said on Monday that remdesivir, the experimental drug being tested for COVID-19, showed that 65 percent of moderately ill patients had improvement after 11 days.



Full story on FOX NEWS ( https://ift.tt/2MmAjbm )